PubMed Health⌕ Search

Biomedical subjects

E Scheitza

Publications and source records attributed to E Scheitza.

At least 19 recordsLinked to original sources
PubMed1977

[Effect of the diuretic Etozolin (Gö 687) on renal elimination of water and solutes in subjects with normal renal function (author's transl)].

The novel diuretic ethyl (Z)-(3-methyl-4-oxo-5-piperidino-thiazolidin-2-ylidene)acetate (etozolin, Gö 687, Elkapin) has been investigated on 10 volunteers with intact renal function. Administration of 800 mg of the compound caused a significant increase of the renal elimination of water, sodium, chloride magnesium as well as of the sum of the osmotic constituents while an influence on the creatinine-clearance could not be demonstrated. Potassium elimination was also raised, however, at the same time the sodium-potassium ration increased strongly. Due to its long-lasting action etozolin seems particularly indicated for the treatment of cardiac and renal edema as well as for the treatment of hypertension.

Adult↗
PubMed1977

[Effect of the diuretic Etozolin in patients with normal and impaired renal function (author's transl)].

The effect of the novel diuretic ethyl (Z)-(3-methyl-4-oxo-5-piperidino-thiazolidin-2-ylidene) acetate (etozolin, Gö 687, Elkapin) on renal function and especially on the elimination of solutes has been investigated under clearance conditions on 25 hydrated patients with different glomerular filtration rates (GFR). On normal persons the compound caused a decrease of GFR and of urea elimination while the absolute and the fractional elimination of sodium and chloride as well as the fractional potassium clearance increased significantly. In patients with chronic renal insufficiency (GFR less than 20 ml/min) these values could not be influenced. A significant correlation between initial GFR and decrease of GFR as well as between initial GFR and increase of renal elimination of sodium and chloride could be demonstrated: the lower the initial GFR the weaker the elimination of electrolytes and the decrease of the filtration rate, the latter being neglible at an initial GFR of 80 ml/min or less.

Adult↗
PubMed1976

[Urographic effects of different states of diuresis (author's transl)].

In 35 patients with normal renal function antidiuretic hormone (DDAVP) effected a significant contraction of renal pelvis and calices, while in 10 other cases an enlargement of the roentgenological size of the kidneys was caused by the administration of the diuretic furosemide (Lasix). These results suggest a dependence of urographic findings from the state of diuresis.

Diagnostic Errors↗
PubMed1976

[Renal function and water and electrolyte balance during i.v. infusion of fenoterol (Partusisten) (author's transl)].

Renal function and electrolyte transport during i.v. Fenoterol treatment (0,021 +/- 0,008 mug/kg/min) were measured in 10 healthy, nonpregnant patients by means of clearance studies utilizing water diuresis. Three 10-min control periods were followed by 9 experimental periods conducted over altogether 90 min., during which the following parameters were measured: diuresis (V), glomerular filtrate (CIn), renal plasma flow (CPAH), urinary and plasma osmolality plasma levels of Na, K and Cl, and their urinary excretion. During Fenoterol infusion, diuresis fell on average from 13.1 in the controls to 6,0 ml/min (p less than 0,01), with a concurrent rise of U/P osmol from 0,215 to 0,984 (p less than 0,01). CIn and CPAH did not change significantly, nor were there any fluctuations in plasma Na and Cl and the respective urinary excretions. The plasma potassium concentration decreased from 3,7 in the controls to 2,7 mEq/l (p less than 0,01) and was associated with a simultaneous fall of the potassium excretion from 0,060 to 0,024 mEq/l (p less than 0,01). The demonstrated antidiuretic action of Fenoterol would appear to be due, as in the case of other betamimetic drugs, to endogenous release of ADH. As shown by our experiments, the fall in plasma K is not attributable to renal factors but may be explained by displacement of K into the cell.

Adult↗
PubMed1975

[Effect of 1-desamino-8-D-arginine-vasopressin in limited renal function].

U-Deamino-8-D-arginine-vasopressin (DDAVP) is a new synthetic antidiuretic hormone with prolonged action. 0.02 mg given intranasally to 38 patients with far advanced chronic renal failure effected an instantaneous decrease in urine volume as well as an augmentation of U/P-inulin ratio, fraction of filtered sodium and chloride excreted and of the absolute elimination of these ions. These findings suggest an improvement of permeability at the descending limb of Henle, too, the latter and a diminution of circulation in the renal medulla being responsible for the increase in renal salt loss after DDAVP. A rise of blood pressure or other side effects could not be observed.

Administration, Intranasal↗